<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430857</url>
  </required_header>
  <id_info>
    <org_study_id>17-5-2015</org_study_id>
    <nct_id>NCT02430857</nct_id>
  </id_info>
  <brief_title>Osteopathy and Latent Hypothyroidism</brief_title>
  <official_title>Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emanuel Amier Diekmann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diekmann, Emanuel Amier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effectiveness of stimulating the neurological segments c8-th5 in&#xD;
      patients with latent hypothyroidism.&#xD;
&#xD;
      One half of the participants will receive an osteopathic manuel treatment in order to&#xD;
      stimulate the relevant segments, the other half will receive no treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with latent hypothyroidism show an increased hormone status in TSH and a normal&#xD;
      hormone status in fT4. A study has shown that osteopathic treatment had positive effects to&#xD;
      some symptoms in patients with latent hypothyroidism. The study was using the pain inventory&#xD;
      as the instrument to measure the effect. In this study we want to evaluate the effectiveness&#xD;
      of the treatment on the hormone status (TSH, fT4) The intervention group will receive a&#xD;
      neurological osteopathic stimulation over 5 weeks. A parallel control group will not receive&#xD;
      any therapy.&#xD;
&#xD;
      A follow up blood screening (TSH, fT4) will be done. The results of both groups will be&#xD;
      compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TSH Concentration</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Latent Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>OMT-Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controll Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will receive no treatment. A blood screening is made again after 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OMT</intervention_name>
    <description>Manuel osteopathic treatment of the spine</description>
    <arm_group_label>OMT-Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  latent hypothyroidism&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Factors that Alter Thyroxine and Triiodothyronine Binding in Serum&#xD;
&#xD;
          -  Increased thyroxin-binding globulin&#xD;
&#xD;
          -  Decreased thyroxin-binding globulin&#xD;
&#xD;
          -  Binding inhibitors&#xD;
&#xD;
          -  Inherited Salicylates&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Androgens&#xD;
&#xD;
          -  Furosemide&#xD;
&#xD;
          -  Neonatal state&#xD;
&#xD;
          -  Anabolic steroids&#xD;
&#xD;
          -  Free fatty acids&#xD;
&#xD;
          -  Estrogens&#xD;
&#xD;
          -  Glucocorticoids&#xD;
&#xD;
          -  Phenytoin&#xD;
&#xD;
          -  Hepatitis&#xD;
&#xD;
          -  Severe illness&#xD;
&#xD;
          -  Carbamazepine&#xD;
&#xD;
          -  Porphyria&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  nonsteroidal antiinflammatory drug (variable, transient)&#xD;
&#xD;
          -  Heroin&#xD;
&#xD;
          -  Nephrosis&#xD;
&#xD;
          -  Heparin&#xD;
&#xD;
          -  Methadone&#xD;
&#xD;
          -  Nicotinic acid&#xD;
&#xD;
          -  Mitotane L-Asparaginase&#xD;
&#xD;
          -  5-Fluorouracil&#xD;
&#xD;
          -  SERMS (e.g., tamoxifen, raloxifene)&#xD;
&#xD;
          -  Perphenazine&#xD;
&#xD;
          -  spinal pathologies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuel Diekmann, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis fuer Osteopathy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuel Diekmann, DO</last_name>
    <phone>0041788800341</phone>
    <email>Emanuel.diekmann@gmx.de</email>
  </overall_contact>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Diekmann, Emanuel Amier</investigator_affiliation>
    <investigator_full_name>Emanuel Amier Diekmann</investigator_full_name>
    <investigator_title>DO</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

